Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer BARCELONA, Sept. 14, 2024 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) today […]
STOCKHOLM, Sept. 13, 2024 /PRNewswire/ — Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 […]
SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and […]
TAIPEI, Sept. 11, 2024 /PRNewswire/ — TCI Co. Ltd. (“TCI”, 8436.TWO), a global leader in ODM health and cosmetic products for over 40 years, introduces its cutting-edge GLP-1 formula, a natural blend of plant extracts, […]
The first real-world analysis of tinnitus patients treated with Lenire in the United States has been submitted to a journal for peer-review and is now available on an online pre-print server for health services, medRxiv. Real-world […]